High-throughout sequencing of ovarian cancer cells treated with Annonacin and Carboplation

The high-throughput sequencing technology was performed after the treatment of human ovarian cancer cells A2780 and ES2 with Annonacin and Carboplation purchased from MCE, to explore the expression of genes related to cell proliferationand DNA damage of ovarian cancer cells A2780 and ES2 after the treatment of Annonacin and Carboplation, and to find an interesting target pathway,p53 signaling pathway. Overall design: A2780 and ES2 cells (3 × 105 cells/well in 6-well plates) were treated with Annonacin or carboplatin or the combination of Annonacin and carboplatin for 48 h. After treatment, the cells were collected, and total RNA from each group was extracted using TRIzol (TaKaRa, Japan). Paired-end sequencing was ultimately carried out on an Illumina HiSeq 4000 platform at LC-BIO Technologies (Hangzhou, China).